Tristel welcomes Dr Bruno Holthof to its Board as Non-Executive Director

– UK, Snailwell –  Tristel plc (LON:TSTL), the manufacturer of infection prevention and contamination control products utilising proprietary chlorine dioxide chemistry, announces the appointment of Dr. Bruno Holthof to its Board as a non-executive director.

Commenting on the appointment, Paul Swinney, CEO of Tristel, said: “We are delighted to welcome Bruno to our Board. Bruno has more than 10 years of board level experience on publicly listed companies. He also brings to the Board an in-depth knowledge and operational experience of healthcare systems in different markets. We very much look forward to working together.”

About Dr. Bruno Holthof

Dr. Bruno Holthof is the Chief Executive Officer of Oxford University Hospitals. Before OUH, he was CEO of the Antwerp Hospital Network from January 2004 until September 2015. Bruno Holthof is also Chair of the Board of Armonea, a European private care home provider.

Before becoming a CEO, he was a partner at McKinsey & Company. During this period, he served a wide range of healthcare clients in Europe and the United States and gained significant expertise in the areas of strategy, organisation and operations. He holds an MBA from the Harvard Business School and an MD/PhD from the University of Leuven.

For more information : http://www.tristel.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.